Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
Total Valuation
Beam Therapeutics has a market cap or net worth of $1.46B. The enterprise value is $1.36B.
Market Cap$1.46B
Enterprise Value$1.36B
Share Statistics
Beam Therapeutics has 99.84M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99.84M
Owened by Insiders26.97%
Owened by Instutions0.09%
Financial Efficiency
Beam Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -44.44%.
Return on Equity (ROE)-51.36%
Return on Assets (ROA)-34.13%
Return on Invested Capital (ROIC)-44.44%
Return on Capital Employed (ROCE)-45.08%
Revenue Per Employee$131,507.246
Profits Per Employee-$780,004.141
Employee Count483
Asset Turnover0.06
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Beam Therapeutics is -5.42. Beam Therapeutics’s PEG ratio is -0.03.
PE Ratio-5.42
PS Ratio32.14
PB Ratio2.78
Price to Fair Value2.78
Price to FCF-5.73
Price to Operating Cash Flow-5.88
PEG Ratio-0.03
Income Statement
In the last 12 months, Beam Therapeutics had revenue of $63.52M and earned -$376.74M in profits. Earnings per share was -$4.58.
Revenue$63.52M
Gross Profit$47.04M
Operating Income-$415.57M
Pretax Income-$376.70M
Net Income-$376.74M
EBITDA-383.98M
Earnings Per Share (EPS)-4.58
Cash Flow
In the last 12 months, operating cash flow was -$347.25M and capital expenditures -$8.95M, giving a free cash flow of -$356.19M billion.
Operating Cash Flow-$347.25M
Free Cash Flow-$356.19M
Free Cash Flow per Share-$3.57
Dividends & Yields
Beam Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-17.45%
Earnings Yield-18.46%
Stock Price Statistics
Beta2.42
52-Week Price Change-39.81%
50-Day Moving Average24.65
200-Day Moving Average25.38
Relative Strength Index (RSI)27.85
Average Volume (3m)2.85M
Important Dates
Beam Therapeutics upcoming earnings date is May 13, 2025, TBA.
Last Earnings DateFeb 25, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Beam Therapeutics as a current ratio of 4.82, with Debt / Equity ratio of 0.22
Current Ratio4.82
Quick Ratio4.82
Debt to Market Cap0.08
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Beam Therapeutics has paid $5.43M in taxes.
Income Tax$5.43M
Effective Tax Rate-0.01%
Enterprise Valuation
Beam Therapeutics EV to EBITDA ratio is -4.62, with an EV/FCF ratio of -5.39.
EV to Sales30.24
EV to EBITDA-4.62
EV to Free Cash Flow-5.39
EV to Operating Cash Flow-5.53
Balance Sheet
Beam Therapeutics has $850.74M in cash and marketable securities with $161.43M in debt, giving a net cash position of -$689.32M billion.
Cash & Marketable Securities$850.74M
Total Debt$161.43M
Net Cash-$689.32M
Net Cash Per Share-$6.90
Tangible Book Value Per Share$8.91
Margins
Gross margin is 100.00%, with operating margin of -654.25%, and net profit margin of -593.13%.
Gross Margin100.00%
Operating Margin-654.25%
Pretax Margin-593.06%
Net Profit Margin-593.13%
EBITDA Margin-654.25%
EBIT Margin-654.25%
Analyst Forecast
The average price target for Beam Therapeutics is $45.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.33
Price Target Upside193.02%
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast-83.18%
EPS Growth Forecast-144.95%